Accuray Incorporated (ARAY) and Halifax Health have teamed up to revolutionize cancer treatment at the Charles L. and Miki N. Grant Cancer Center for Hope in Port Orange, Florida. The center’s medical team has become the first in the United States to treat cancer patients using Accuray’s Radixact System with VitalHold technology. This innovative system marks a significant advancement in radiation therapy, offering a new standard of care for a wide range of cancer cases, including breast cancer.
The Radixact System, backed by VitalHold and other advanced technologies like ClearRT helical CT imaging and Synchrony real-time adaptive delivery, provides unparalleled precision in radiation therapy. VitalHold’s surface-guided radiotherapy (SGRT) ensures accurate patient positioning, improving the reproducibility of treatments and enabling deep inspiration breath hold techniques. This minimizes radiation exposure to critical organs, reducing long-term complications. The system’s tattoo-free positioning further enhances patient experience, making radiation therapy more comfortable and cosmetically appealing.
The anticipated 35% increase in new cancer cases in the United States by 2040 underscores the critical need for advanced resources. Accuray’s Radixact System, equipped with the VitalHold feature, is designed to meet this challenge by providing precise, high-quality radiation therapy from simulation through delivery.
The partnership between Accuray and Halifax Health, where the first U.S. patients have been treated using this innovative system, highlights Accuray’s commitment to pushing the boundaries of cancer treatment.
The global radiation therapy market is experiencing robust growth, driven by the rising incidence of cancer and advancements in radiation therapy technology. According to Precedence Research, the global radiation therapy market size is expected to be worth $7.47 billion in 2024, reaching $16.30 billion by 2033 at a CAGR of 8.6%.
The integration of innovative features and software systems in radiation therapy will enhance performance, driving increased demand and market value during the forecast period. In June, Accuray announced that Heidelberg University Hospital in Germany is set to adopt its Radixact System, replacing its older TomoTherapy System.
While Accuray leads the way with the Radixact System, other companies in the medical instruments industry are also making notable developments in their respective areas. AngioDynamics, Inc. (ANGO) is a pioneering medical technology company dedicated to advancing vascular health and cancer treatment. Intuitive Surgical, Inc. (ISRG) is a global leader in minimally invasive care and a pioneer of robotic surgery. Masimo Corporation (MASI) is a global medical technology company specializing in advanced monitoring technologies.
The advancements in cancer treatment technology, like the Radixact System, represent a brighter future for patients facing cancer. As technology continues to evolve, we can expect even more innovative and effective treatments to emerge, improving the lives of countless individuals.
